NCT03192202View on ClinicalTrials.gov

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
DRUG

AFM13

AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.

Trial Locations (1)

10019

Center for Lymphoid Malignancies, New York

All Listed Sponsors
lead

Ahmed Sawas

OTHER

NCT03192202 - AFM13 in Relapsed/Refractory Cutaneous Lymphomas | Biotech Hunter | Biotech Hunter